FDA has labeled a DexCom alert about alarm activation failures with its G4 Platinum and G5 Mobile continuous glucose monitoring systems as a class I recall.
DexCom Inc.'s February alert about alarm problems with its G4 Platinum and G5 Mobile continuous glucose monitors for diabetics has been tagged as a class I recall, FDA said
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
FDA Commissioner Marty Makary stated in a new interview that there will be no significant reorganization of the agency, despite earlier reports. Using his “guiding principles” of common sense and gold-standard science, he plans to focus on reforms including improved pathways for medical AI and food safety as well as addressing employee morale.
As the EU Life Sciences Strategy aims to drive innovation, the medtech sector is pushing for a pivotal role in a mission intended to embrace green and digital transitions, address regulatory obstacles and reduce dependency on external sources.
Former FDA Commissioner Robert Califf urged the Heart Rhythm Society to engage actively amid federal funding cuts. He highlighted collaboration among researchers, advocates for healthcare integration, and the importance of addressing social determinants of health, while discussing lobbying strategies and the challenges faced by medtech companies.
